Abbott Labs (ABT) recent acquisition of Solvay is a lead indicator for a new wave of acquisitions of Biotech companies by Large Pharmaceutical companies like Pfizer (PFE), Bristol Myers (BMY) and Novartis (NVS) according to Serge Depatie, portfolio manager for NatCan Investments. One target that Mr. Depatie thinks will make a good acquisition is Orexigen (OREX) which is focused on obesity treatments.
